Amniotic Membrane for Dry Eye: When It May Help

The short answer: what amniotic membrane can and cannot do

An amniotic membrane may help selected people with severe, treatment-resistant, or complicated dry eye, particularly when an examination shows corneal staining, epithelial breakdown, a persistent defect, reduced corneal sensitivity, exposure-related injury, or poor healing. It is processed tissue derived from donated placenta and placed temporarily over the ocular surface as a biological bandage.

This is not presented in the available evidence as routine first-line care for uncomplicated dry eye. Its clearest role is short-term protection and healing support for a compromised corneal surface. A 2020 narrative review reported favorable epithelial, symptom, and visual outcomes in affected eyes treated with cryopreserved amniotic membrane, but it also called for randomized controlled trials (2020 review of amniotic membrane for dry eye and neurotrophic keratitis).

The key word is selected. Burning, grittiness, or fluctuating vision can be severe without meaning that the cornea needs a membrane. Candidacy therefore depends on examination findings, the likely cause, and how the eye has responded to previous treatment—not symptom intensity alone.

It also helps to separate four outcomes that are often conflated:

1. Symptom relief: Does the eye feel less painful, gritty, or irritated?
2. Epithelial healing: Does damaged surface tissue close and become healthier?
3. Visual improvement: Does vision improve as an irregular or damaged corneal surface recovers?
4. Durable disease control: Does the underlying cause remain controlled after the membrane is gone?

These outcomes do not necessarily occur together. A membrane could support epithelial healing without curing the process that caused the damage. Vision may improve when surface irregularity clears, but improvement is not guaranteed.

An amniotic membrane also does not automatically correct low tear production, meibomian gland dysfunction, incomplete blinking, poor eyelid closure, medication effects, autoimmune disease, or infection. Most patients still need cause-directed treatment before, during, or after membrane therapy.

Amniotic membrane is best understood as a temporary corneal-protection and healing intervention—not a guaranteed cure for dry-eye disease.

What the membrane is and why clinicians place it on the cornea

Amniotic membrane is an avascular fetal membrane obtained from donated placental tissue and processed for medical use. It contains an epithelial layer, basement membrane, and stromal tissue. Donor screening and tissue processing are intended safeguards, but they should not be interpreted as eliminating every tissue-related risk (American Academy of Ophthalmology overview of in-office amniotic membrane).

Its most direct role is physical

When placed over the cornea, an intact membrane forms a temporary covering between the injured surface and the eyelids. That covering may:

• Shield fragile epithelium from repeated eyelid friction
• Reduce mechanical disruption during blinking
• Support epithelial-cell migration and adhesion
• Protect an erosion or defect while the surface repairs
• Reduce exposure to environmental irritation

This physical role is important because blinking can repeatedly disturb unhealthy or poorly attached epithelium. Temporarily reducing that friction may give the cornea a better opportunity to close a defect or recover from widespread surface injury.

Proposed biological actions are not guaranteed outcomes

Amniotic tissue is also used because it is proposed to modulate inflammation and fibrosis and to support epithelial repair. Those properties provide a rationale for treatment, but they do not mean every patient will experience less inflammation, avoid scarring, or obtain meaningful symptom relief.

Claims of antimicrobial action require particular caution. The mechanism has been described as controversial and may reflect the membrane’s physical barrier or chemical environment rather than a dependable infection-treating effect. A membrane is not a substitute for antimicrobial evaluation and treatment when infection is suspected.

Dry eye is more than “not enough tears”

Dry-eye disease can involve tear-film instability, inflammation, ocular-surface damage, and neurosensory abnormalities. Different people can reach a damaged corneal surface through different pathways, including:

• Insufficient aqueous tear production
• Excess evaporation associated with meibomian gland dysfunction
• Incomplete or infrequent blinking
• Poor eyelid closure
• Exposure after surgery or facial-nerve dysfunction
• Medication or systemic-disease effects
• Reduced corneal sensitivity and impaired healing

Corneal nerves contribute to sensation, reflex blinking, tear secretion, and epithelial maintenance. When corneal sensitivity is reduced, blinking and tearing reflexes may weaken and epithelial healing may become less effective.

This creates potential overlap between dry eye and neurotrophic keratitis, a degenerative corneal condition associated with impaired trigeminal innervation and reduced corneal sensitivity. They are not interchangeable diagnoses.

That distinction changes the purpose of treatment. A membrane placed for tear-film-related irritation is not addressing the same clinical problem as one placed over a persistent epithelial defect in an eye with reduced sensation.

Corneal nerve regeneration has been proposed as one possible explanation for longer-term benefit, but it remains a research question. Preclinical findings and indirect clinical observations do not prove that amniotic membrane regenerates corneal nerves in humans.

Who may be a candidate—and who probably is not

The most useful candidacy assessment combines objective corneal findings, likely causes, and treatment history. There is no universal prerequisite list or standardized definition of treatment failure in the supplied evidence.

A more plausible candidate

A clinician may be more likely to discuss an amniotic membrane when several of these features are present:

• Severe or persistent symptoms despite appropriate prior care
• Significant corneal staining
• Epithelial breakdown, erosion, or a persistent epithelial defect
• Poor healing after surgery or injury
• Reduced corneal sensitivity
• Exposure-related damage from incomplete blinking or eyelid closure
• Neurotrophic features
• Ocular-surface inflammation with concern about continuing damage
• A need for temporary protection while other treatment takes effect

A patient-facing clinical source similarly describes evaluation of tear-film quality, eyelid health, ocular-surface integrity, and contributing factors before treatment, while framing the membrane as one part of longer-term care rather than a standalone cure (clinical overview of amniotic membranes in dry-eye management).

A less plausible candidate

Consider someone with evaporative dry eye associated with meibomian gland dysfunction. Symptoms worsen during prolonged screen use and improve somewhat with blinking or lubricating drops. Corneal staining is minimal, sensitivity is normal, and there is no epithelial defect.

That person may be very uncomfortable, but a membrane would not restore normal oil-gland function or correct prolonged incomplete blinking. Eyelid treatment, tear-film support, environmental changes, and other subtype-directed measures address the apparent mechanism more directly.

Now contrast that with someone who has persistent epithelial breakdown, reduced corneal sensitivity, incomplete eyelid closure, and poor healing despite prior treatment. In that setting, temporary biological coverage has a clearer purpose: protect the cornea and support closure while the clinician also addresses exposure and the underlying condition.

Conditions that complicate the decision

Several contributors can alter diagnosis, treatment choice, and monitoring:

• Incomplete blinking or poor eyelid closure: A membrane does not correct the eyelid mechanics causing exposure.

• Contact-lens wear: Lenses may need to be stopped while the cause of surface injury is assessed.

• Possible infection: A biological covering cannot replace diagnosis and antimicrobial management.

Suspected infectious keratitis requires prompt clinical evaluation and appropriate antimicrobial treatment. If a membrane is used, it must be clinician-directed adjunctive protection rather than a replacement for infection treatment.

What the examination should cover

Before recommending a membrane, an eye-care clinician may assess:

• Tear-film stability and volume
• Eyelid position, closure, and blinking
• Meibomian gland and lid-margin findings
• Corneal and conjunctival staining
• Whether an epithelial defect is present
• Corneal sensitivity
• Signs of infection or significant inflammation
• Recent surgery, injury, medications, and systemic disease
• Previous treatments, adherence, benefit, and intolerance
• Whether symptoms and examination findings suggest the same mechanism

The recommendation should then be tied to a defined goal. “Treat dry eye” is too broad. “Protect a persistent epithelial defect and support closure” or “reduce friction while an exposure-related surface injury heals” provides a clearer endpoint.

Cryopreserved, dehydrated, ring-mounted, and liquid formats

Amniotic-membrane treatments are not interchangeable. Preservation, device design, placement, removal, visual effect, and supporting evidence can differ. Product-specific instructions should take priority over general descriptions.

Format	Preservation	How it may be held on the eye	Removal pathway	Likely effect on vision	Evidence boundary
Cryopreserved, ring-mounted solid membrane	Stored frozen	Membrane is mounted in a flexible ring positioned beneath the eyelids	Tissue may dissolve or be absorbed; the ring is removed by a clinician	Can substantially blur the treated eye when the membrane covers the visual axis	Much favorable discussion concerns cryopreserved membrane, but controlled dry-eye comparisons remain limited
Cryopreserved membrane without an integrated ring	Stored frozen	Placement and support depend on the exact product and technique	Product- and technique-dependent	Variable; central coverage may blur vision	Results from a specific ring-mounted device should not automatically be transferred to other designs
Dehydrated solid membrane	Dried for storage and rehydrated for use	May be placed on the cornea and supported with a bandage contact lens	Tissue may dissolve or be absorbed; a supporting lens may require removal	Central placement may cause blur	Clinical use is described, but equivalence or inferiority to cryopreserved tissue is not established
Liquid or particulate preparation	Processed as a liquid, powder, or suspension	Applied to the ocular surface rather than worn as an intact sheet	No ring-removal pathway; handling varies	Functional effects are product-dependent and not well established in the supplied evidence	Equivalence to an intact solid membrane has not been demonstrated

A commonly described cryopreserved product holds the membrane inside a flexible ring. The clinician positions the upper part beneath the upper eyelid and then places the lower part beneath the lower lid, somewhat like inserting a large contact lens.

A dehydrated disk may instead be placed directly on the cornea, rehydrated, and covered by a soft bandage contact lens. These descriptions come largely from professional education, manufacturers, and treatment-providing clinics rather than comparative trials.

Manufacturers may claim that proprietary cryopreservation retains biological activity, while some clinics characterize dehydrated products as emphasizing physical protection. Those statements do not prove that one format produces better healing, comfort, symptom control, or durability.

Liquid and particulate preparations should be considered separately. Applying suspended amniotic-derived material is physically different from keeping an intact biological covering over the cornea. The available evidence does not establish that the two approaches provide equivalent effects.

Before treatment, ask for the exact product name, preservation method, support device, expected wear period, and removal plan. Outcomes from one device or one ocular-surface condition should not be generalized to every product or to routine dry eye.

What treatment is like from examination to removal

Placement is generally described as a brief in-office procedure, but the full visit includes examination, consent, preparation, fit assessment, instructions, and follow-up planning.

1. Examination and treatment goal

The clinician confirms the diagnosis, examines the corneal surface, assesses possible infection and eyelid contributors, and defines the intended outcome. Important questions include:

• Why is a membrane being recommended now?
• Is the goal defect closure, reduced staining, pain relief, or another endpoint?
• Which product and format will be used?
• What alternatives are available?
• How much blur or functional limitation is expected?
• What risks and follow-up requirements apply?
• What will happen if the membrane does not help?

2. Preparation and consent

Contact lenses are removed if applicable. The clinician should explain what the device may feel like, whether the treated eye will be functionally blurred, and what symptoms should prompt an urgent call.

Transportation may be needed if central vision will be obscured.

3. Topical anesthetic

Numbing drops are commonly applied before placement. These can reduce insertion discomfort, but they do not guarantee comfort throughout the wear period.

4. Placement

With a ring-mounted membrane, the clinician positions the device beneath the upper and lower eyelids and checks its fit.

With a dehydrated or unsupported sheet, the tissue may be positioned on the cornea and held in place with a bandage contact lens. The exact method depends on the product and intended use.

5. The first hours

Vision in the treated eye may become markedly blurred if the membrane or device covers the central cornea. Foreign-body sensation, mild discomfort, tearing, and light sensitivity may occur. Some clinicians treat one eye at a time to preserve useful vision in the other, but that is not a universal rule.

6. The wear period

Wear time varies by product and clinical findings. Sources commonly describe several days, while the manufacturer of one ring-mounted product gives a broader possible range of 2 to 30 days (manufacturer patient instructions and product information). That range is not a promise for any individual patient.

Instructions may include:

• Do not rub or press on the eye
• Do not swim or soak the eye
• Do not reposition or remove the device yourself
• Use prescribed drops as directed
• Avoid driving whenever vision is impaired
• Ask before resuming contact-lens wear
• Call if the device moves, falls out, or becomes intolerable

The treating clinician’s instructions take priority because precautions vary by product and condition.

7. Follow-up and removal

At follow-up, the clinician assesses:

• Whether staining or an epithelial defect has improved
• Whether the membrane remains properly positioned
• Whether the tissue has dissolved or been absorbed
• Whether a ring or supporting lens requires removal
• Whether there are signs of infection, inflammation, or intolerance
• Which treatments should continue after removal

Ring-mounted devices are generally removed in the office. With other formats, the clinician may confirm that the tissue has dissolved or remove a supporting contact lens.

Follow-up is not a formality. It determines whether the cornea is healing and whether the broader management plan needs to change.

Potential benefits, expected drawbacks, and warning signs

The most realistic discussion separates plausible benefits from expected burdens and unresolved risks.

Plausible benefits

Protection from friction. An intact membrane can form a temporary barrier between the eyelids and a vulnerable corneal surface.

Support for epithelial closure. A protected surface may make it easier for epithelial cells to migrate and adhere over an erosion or defect.

Reduced surface inflammation. The tissue has proposed inflammation-modulating properties, although the clinical effect varies and is not guaranteed.

Symptom relief. Reduced friction and improved epithelial health may lessen pain, burning, or foreign-body sensation after treatment. The device itself may be uncomfortable while worn.

Possible visual improvement. Staining, epithelial irregularity, and defects can degrade optical quality.

Successful short-term healing therefore does not prove durable dry-eye control.

Expected short-term burdens

Treatment may involve:

• Blurred or substantially reduced vision in the treated eye
• Foreign-body sensation
• Mild discomfort
• Light sensitivity
• Tearing
• Restrictions on driving, swimming, and certain work activities
• Additional eye-drop instructions
• Follow-up visits
• Office removal of a ring or supporting lens

A short placement procedure can still have a meaningful practical impact. Work involving driving, machinery, heights, fine depth judgment, dust, water, or eye-rubbing risk may require modified duties.

What is not known reliably

The supplied evidence does not provide dependable frequencies for:

• Infection
• Device displacement
• Intolerance
• Failure of an epithelial defect to heal
• Worsening inflammation
• Early removal
• Recurrence after initial healing
• Repeat treatment
• Serious tissue-related complications

The absence of reliable rates does not mean these outcomes never occur. Risk should be discussed with reference to the exact product, the condition being treated, and the patient’s medical history.

When to contact the clinician

Contact the treating office promptly for worsening pain, marked redness, swelling, discharge, increasing intolerance, worsening vision, or a device that appears displaced, damaged, or has fallen out. Manufacturer instructions for a ring-mounted product similarly advise contacting the eye doctor about discomfort, swelling, redness, discharge, or other problems and caution against self-removal (manufacturer safety and handling instructions).

Do not try to remove or reposition a ring-mounted device unless the treating clinician has explicitly instructed you to do so. Suspected infection should not be self-treated with leftover medication or assumed to be a routine dry-eye flare.

Under this publication’s safety policy, sudden vision change, eye pain, or light sensitivity warrants same-day clinical attention (Dry Eye Watch safety notice).

What the evidence actually shows

The evidence is best understood as a ladder rather than a single answer.

1. Biological rationale

The membrane’s physical covering, basement-membrane structure, and proposed inflammation- and fibrosis-modulating effects provide a reasonable basis for supporting corneal repair. The rationale is strongest when the goal is concrete: protect damaged epithelium, reduce eyelid friction, or support closure of a defect.

Biological plausibility is not proof of patient-important benefit. Relevant laboratory or structural properties do not guarantee reliable symptom relief or lasting dry-eye control.

2. Mixed-condition clinical literature

Much of the literature combines dry eye with neurotrophic keratitis, exposure keratopathy, persistent epithelial defects, ulcers, and other ocular-surface disorders. These populations often have more structural damage and a clearer need for temporary coverage than someone with uncomplicated evaporative dry eye.

This mixed evidence helps explain why clinicians use membranes on compromised corneas. It does not establish an average response for everyone considering amniotic membrane for dry eye.

3. Individual complex cases

An American Academy of Ophthalmology article describes one patient whose visual acuity improved from 20/100 to 20/25, with corneal staining resolving after seven days of treatment with a cryopreserved device (AAO clinical case and review).

That result cannot predict routine dry-eye outcomes. The patient also had diabetes, exposure keratopathy, incomplete blinking, lagophthalmos, and previous treatment failures. The case is most useful as an illustration of patient selection: the membrane was used for objectively damaged, poorly healing epithelium—not simply because the patient felt dry.

4. Narrative-review conclusions

The 2020 narrative review concluded that the studies it discussed collectively supported restoration of corneal epithelial health, symptom relief in dry-eye disease, and visual improvement in affected eyes treated with cryopreserved amniotic membrane.

That favorable conclusion requires several qualifications:

• The supplied review material does not provide a pooled effect estimate.
• The literature overlaps with neurotrophic and structurally compromised corneas.
• Dry-eye-specific response rates are not established.
• Long-term durability remains uncertain.
• Superiority over other treatments has not been demonstrated.
• The authors called for randomized controlled trials.
• Corneal nerve regeneration was presented as requiring validation, not as a proven effect.
• The authors reported affiliations with TissueTech, an amniotic-tissue company.

A commercial affiliation does not automatically invalidate a publication, but it matters when interpreting favorable conclusions from an evidence base with limited randomized comparative data (peer-reviewed narrative review and author disclosures).

5. Commercial and clinic claims

Manufacturers, treatment-selling clinics, and clinician-created explainers provide much of the practical information about insertion, wear, and day-to-day experience. Those sources can explain how a particular product is used, but they are weaker evidence for effectiveness.

Some promotional sources describe rapid or lasting relief without supplying controlled comparisons, effect sizes, or reliable follow-up. One author of the AAO article disclosed consulting for BioTissue, and a clinician-created product demonstration in the evidence set disclosed affiliate relationships. These contexts do not make every procedural detail wrong, but they reinforce the need to distinguish practical description from proof of benefit.

What remains unestablished

The available evidence does not establish reliable general estimates for:

• The proportion of dry-eye patients who respond
• Average symptom improvement
• Average change in staining or defect size
• Duration of relief
• Recurrence after healing
• Frequency of repeat treatment
• Which dry-eye subtype benefits most
• Whether cryopreserved or dehydrated treatment is better
• Whether liquid preparations are equivalent to solid membranes
• Comparative effectiveness against serum tears, scleral lenses, bandage lenses, prescription drops, punctal plugs, or IPL

The balanced conclusion is that amniotic membrane is promising enough to discuss in selected difficult cases, especially when there is objective epithelial damage or impaired healing. The evidence is not strong enough to guarantee benefit, define a standard treatment sequence, or prove that one clinic’s product is superior.

Where it fits among other dry-eye treatments

Dry-eye treatments are more usefully compared by what they target than ranked from weakest to strongest.

An amniotic membrane chiefly provides short-term corneal coverage and healing support. Other interventions may target lubrication, tear drainage, evaporation, inflammation, eyelid disease, exposure, or optical rehabilitation. More than one approach may be needed because these mechanisms can coexist.

Treatment approach	Main conceptual target	What it does not automatically correct
Artificial tears or lubricating ointment	Supplements surface lubrication and reduces friction	Gland obstruction, infection, systemic disease, or eyelid mechanics
Prescription dry-eye drops	May target inflammatory or tear-film pathways, depending on the medication	A persistent epithelial defect may still need direct protection
Eyelid and meibomian-gland care	Addresses lid-margin disease and poor oil delivery	Aqueous deficiency, neurotrophic disease, or an existing defect
Punctal approaches	Reduce tear drainage so tears remain on the surface longer	Tear quality, infection, poor blinking, or gland obstruction
IPL	Presented clinically as targeting inflammation and meibomian gland dysfunction in selected patients	Direct coverage of an epithelial defect
Bandage contact lens	Provides mechanical corneal protection	Does not provide amniotic tissue
Serum tears	Provides biologically derived tear supplementation in selected ocular-surface conditions	Does not create the same continuous physical covering
Scleral lens	Vaults the cornea and maintains a fluid reservoir during wear	Does not inherently correct systemic disease or every inflammatory or eyelid cause
Amniotic membrane	Temporarily protects the surface and supports epithelial repair	Does not automatically correct the process that caused the damage

Patient-facing comparisons describe punctal plugs as reducing tear drainage and IPL as addressing inflammation and meibomian gland dysfunction, but these descriptions do not establish either a treatment sequence or comparative superiority (overview of punctal plugs, IPL, and amniotic membranes).

The table is conceptual, not a comparative-effectiveness ranking. The supplied evidence does not support claims that amniotic membrane is better or worse than serum tears, scleral lenses, bandage lenses, prescription anti-inflammatory drops, punctal plugs, or IPL.

Why treatment may continue after removal

If a membrane helps a defect close but aqueous deficiency remains, tear supplementation or prescription treatment may continue. If incomplete blinking caused exposure, eyelid protection is still necessary. If meibomian gland dysfunction destabilizes the tear film, lid-directed care may remain part of the plan. Autoimmune contributors may require coordinated systemic and ocular management.

The membrane is therefore often a bridge or adjunct: it protects the cornea during a vulnerable period while longer-term treatment addresses the cause.

Questions to ask before agreeing to treatment

Bring these questions to the appointment:

• What is my exact diagnosis?
• Is this dry eye alone, or is there exposure keratopathy, neurotrophic keratitis, an erosion, or a persistent epithelial defect?
• What objective corneal finding supports use of a membrane?
• Has corneal sensitivity been checked?
• What outcome are we trying to achieve?
• Which exact product and format will be used?
• Is it cryopreserved, dehydrated, ring-mounted, contact-lens-supported, or liquid?
• Why is that format appropriate for my eye?
• How long do you expect it to remain in place?
• Will it dissolve, or must something be removed?
• How blurred is my vision likely to be?
• Can I work, read, use screens, or drive?
• What restrictions apply to bathing, swimming, exercise, and eye rubbing?
• What alternatives address my underlying dry-eye mechanism?
• What risks are relevant to my health history and this product?
• When is follow-up, and whom do I contact after hours?
• What counts as treatment success or failure?
• How durable do you expect the result to be?
• What is the plan if the problem recurs?
• Would repeat treatment be considered?
• Which existing treatments should continue?
• What is the expected total cost?
• Is prior authorization required?
• What will I owe if coverage is denied?

Reliable cost and coverage figures are unavailable from the supplied evidence. They may vary by diagnosis, product, clinician, billing requirements, insurer policy, and prior authorization. Ask the practice to verify benefits and provide a written estimate.

Frequently asked questions

Does insertion of an amniotic membrane hurt?

Topical anesthetic drops are generally used before placement, so insertion may involve pressure or awareness rather than sharp pain. Once the numbing effect wears off, a ring-mounted device or supporting contact lens can cause foreign-body sensation, mild discomfort, tearing, or light sensitivity. Clinic procedure descriptions also advise arranging transportation because vision may be temporarily blurred (patient overview of the placement process).

“Not painful to insert” is not the same as “comfortable to wear.” Contact the treating clinician if discomfort becomes severe, steadily worsens, or occurs with marked redness, swelling, discharge, or declining vision.

How long does an amniotic membrane stay on the eye?

Often several days, but there is no universal wear period. Timing depends on the product, device design, clinical findings, and whether the tissue dissolves, is absorbed, or leaves behind a ring or supporting lens that requires office removal.

Follow the timetable for the exact device used rather than assuming that another patient’s schedule applies to you.

Can I drive, work, read, or use screens while wearing it?

Expect some degree of blur in the treated eye, potentially substantial blur when an opaque membrane or device covers the central cornea. Do not drive whenever vision is impaired or the treating clinician has advised against it.

Whether reading, screen use, or work is practical depends on vision in the other eye, discomfort, light sensitivity, job demands, and the device. Work involving driving, machinery, heights, dust, water, or fine depth judgment may require modified duties.

Plan transportation for placement and follow-up unless the treating office confirms that it is unnecessary.

Is cryopreserved amniotic membrane better than dehydrated membrane?

Not on the basis of the supplied evidence. Cryopreserved products are often said to retain biological activity, while dehydrated products are commonly described as providing physical surface protection and simpler storage. These descriptions do not prove that one produces better dry-eye outcomes.

The favorable review evidence focuses largely on cryopreserved membrane, but that is not a direct head-to-head comparison. Product choice should reflect the condition being treated, intended outcome, device design, clinician experience, removal method, practical limitations, evidence for the exact product, and cost.

Will insurance cover amniotic membrane treatment for dry eye?

It may or may not. The supplied evidence does not support a reliable coverage percentage or typical out-of-pocket price.

Before treatment, ask the office to:

• Confirm the diagnosis that will be submitted
• Check whether prior authorization is required
• Verify whether the product and procedure are covered
• Estimate your deductible, coinsurance, or self-pay amount
• Explain what happens financially if the claim is denied

Amniotic membrane is best understood as a temporary corneal-healing intervention for selected difficult cases—not a universal dry-eye remedy. The central questions are whether there is objective surface damage or impaired healing, what exact result treatment is intended to achieve, which format will be used, what functional limitations and risks apply, and which cause-directed treatments will still be needed afterward.

Sudden vision change, eye pain, or light sensitivity merits same-day clinical attention.